Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension.
Saved in:
| Title: | Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. |
|---|---|
| Authors: | Moon JS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea., Han KA; Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, South Korea., Yu JM; Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, South Korea., Won JC; Division of Endocrinology and Metabolism, Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, South Korea., Kang JG; Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea., Park S; JW Pharmaceutical Corporation, Gwacheon-si, Gyeonggi-do, South Korea., Park CY; Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: cydoctor@skku.edu. |
| Source: | Diabetes research and clinical practice [Diabetes Res Clin Pract] 2026 Jun; Vol. 236, pp. 113272. Date of Electronic Publication: 2026 Apr 24. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42036072 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Moon+JS%22">Moon JS</searchLink>; Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea.<br /><searchLink fieldCode="AU" term="%22Han+KA%22">Han KA</searchLink>; Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Yu+JM%22">Yu JM</searchLink>; Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Won+JC%22">Won JC</searchLink>; Division of Endocrinology and Metabolism, Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, South Korea.<br /><searchLink fieldCode="AU" term="%22Kang+JG%22">Kang JG</searchLink>; Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, South Korea.<br /><searchLink fieldCode="AU" term="%22Park+S%22">Park S</searchLink>; JW Pharmaceutical Corporation, Gwacheon-si, Gyeonggi-do, South Korea.<br /><searchLink fieldCode="AU" term="%22Park+CY%22">Park CY</searchLink>; Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: cydoctor@skku.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228508335%22">Diabetes research and clinical practice</searchLink> [Diabetes Res Clin Pract] 2026 Jun; Vol. 236, pp. 113272. <i>Date of Electronic Publication: </i>2026 Apr 24. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>8508335 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-8227 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201688227%22">01688227 </searchLink><i>NLM ISO Abbreviation: </i>Diabetes Res Clin Pract <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42036072 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.diabres.2026.113272 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 113272 Titles: – TitleFull: Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Moon JS – PersonEntity: Name: NameFull: Han KA – PersonEntity: Name: NameFull: Yu JM – PersonEntity: Name: NameFull: Won JC – PersonEntity: Name: NameFull: Kang JG – PersonEntity: Name: NameFull: Park S – PersonEntity: Name: NameFull: Park CY IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2026 Jun Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1872-8227 Numbering: – Type: volume Value: 236 Titles: – TitleFull: Diabetes research and clinical practice Type: main |
| ResultId | 1 |
